

Market Announcement



23 October 2026

Resonance Health Limited (ASX: RHT) – Trading Halt

Trading in the securities of Resonance Health Limited ('RHT') will be halted at the request of RHT, pending the release of an announcement by RHT.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Tuesday, 27 October 2026; or
- the release of the announcement to the market.

RHT's request for a trading halt is attached below for the information of the market.

Issued by

ASX Supervision

22 October 2026

Sam Dorland
ASX Limited
Level 40, Central Park
152-158 St Georges Terrace
PERTH WA 6000
Australia

By email:

Sam.Dorland@asx.com.au

tradinghaltsperth@asx.com.au

Dear Sam

Request for Trading Halt: Resonance Health Ltd (ASX: RHT) (Company)

We request a trading halt to be applied to our ordinary securities pursuant to ASX Listing Rule 17.1 and set out below details of the request:

1. We would like the trading halt to commence from the commencement of trading on 23 October 2026.
2. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a market sensitive announcement in relation to (i) the preliminary results of its Liver Fibrosis Extended-Proof-of-Concept clinical trial, and (ii) a placement to sophisticated and/or institutional investors (**Announcement**).
3. The trading halt is to last until the earlier of the commencement of normal trading on Tuesday 27 October 2026 or when the Company releases the Announcement.

We are not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Please contact me if you require any further information.

Yours sincerely

A handwritten signature in black ink, appearing to read "Mitchell Wells".

Mitchell Wells

Non-executive Director & Company Secretary
Resonance Health Ltd